Ludema Christina, Cole Stephen R, Eron Joseph J, Edmonds Andrew, Holmes G Mark, Anastos Kathryn, Cocohoba Jennifer, Cohen Mardge, Cooper Hannah L F, Golub Elizabeth T, Kassaye Seble, Konkle-Parker Deborah, Metsch Lisa, Milam Joel, Wilson Tracey E, Adimora Adaora A
*Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC;Departments of †Epidemiology;‡Health Policy and Management, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC;§Departments of Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY;‖Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA;¶Department of Medicine, Cook County Health and Hospital System, Rush University, Chicago, IL;**Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA;††Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;‡‡Division of Infectious Diseases and Travel Medicine, Department of Medicine, Georgetown University, Washington, DC;§§Division of Infectious Diseases, University of Mississippi Medical Center, Jackson, MS;‖‖Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY;¶¶Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA; and***Department of Community Health Sciences, School of Public Health, State University of New York (SUNY) Downstate Medical Center, Brooklyn, NY.
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):307-312. doi: 10.1097/QAI.0000000000001078.
Implementation of the Affordable Care Act motivates assessment of health insurance and supplementary programs, such as the AIDS Drug Assistance Program (ADAP) on health outcomes of HIV-infected people in the United States. We assessed the effects of health insurance, ADAP, and income on HIV viral load suppression.
We used existing cohort data from the HIV-infected participants of the Women's Interagency HIV Study. Cox proportional hazards models were used to estimate the time from 2006 to unsuppressed HIV viral load (>200 copies/mL) among those with Medicaid, private, Medicare, or other public insurance, and no insurance, stratified by the use of ADAP.
In 2006, 65% of women had Medicaid, 18% had private insurance, 3% had Medicare or other public insurance, and 14% reported no health insurance. ADAP coverage was reported by 284 women (20%); 56% of uninsured participants reported ADAP coverage. After accounting for study site, age, race, lowest observed CD4, and previous health insurance, the hazard ratio (HR) for unsuppressed viral load among those privately insured without ADAP, compared with those on Medicaid without ADAP (referent group), was 0.61 (95% CI: 0.48 to 0.77). Among the uninsured, those with ADAP had a lower relative hazard of unsuppressed viral load compared with the referent group (HR, 95% CI: 0.49, 0.28 to 0.85) than those without ADAP (HR, 95% CI: 1.00, 0.63 to 1.57).
Although women with private insurance are most likely to be virally suppressed, ADAP also contributes to viral load suppression. Continued support of this program may be especially critical for states that have not expanded Medicaid.
《平价医疗法案》的实施促使人们对医疗保险及补充项目进行评估,比如美国针对感染艾滋病毒者的艾滋病药物援助项目(ADAP)对健康结果的影响。我们评估了医疗保险、ADAP和收入对艾滋病毒载量抑制的作用。
我们使用了女性机构间艾滋病毒研究中感染艾滋病毒参与者的现有队列数据。采用Cox比例风险模型来估计2006年至艾滋病毒载量未得到抑制(>200拷贝/毫升)的时间,这些参与者分别拥有医疗补助、私人保险、医疗保险或其他公共保险,以及没有保险,按是否使用ADAP进行分层。
2006年,65%的女性拥有医疗补助,18%拥有私人保险,3%拥有医疗保险或其他公共保险,14%表示没有医疗保险。284名女性(20%)报告有ADAP覆盖;56%未参保的参与者报告有ADAP覆盖。在考虑了研究地点、年龄、种族、观察到的最低CD4水平和既往医疗保险情况后,与没有ADAP的医疗补助参保者(参照组)相比,没有ADAP的私人保险参保者中病毒载量未得到抑制的风险比(HR)为0.61(95%置信区间:0.48至0.77)。在未参保者中,与参照组相比,有ADAP的人病毒载量未得到抑制的相对风险低于没有ADAP的人(HR,95%置信区间:0.49,0.28至0.85)(HR,95%置信区间:1.00,0.63至1.57)。
虽然拥有私人保险的女性最有可能实现病毒抑制,但ADAP也有助于病毒载量的抑制。对于尚未扩大医疗补助覆盖范围的州而言,持续支持该项目可能尤为关键。